Sickle cell disease (SCD) is the most common monogenic hematologic disorder and is
essentially congenital hemolytic anemia caused by an inherited point mutation in the β …

This article provides an overview of conventional, new, and future treatment options for
sickle cell disease (SCD), a genetic disorder affecting the production of hemoglobin. Current …

Introduction Sickle cell disease (SCD) describes a group of heritable blood disorders
caused by the polymerization of sickle hemoglobin (HbS). HbS polymerization leads to …

Conspectus Sickle cell disease (SCD) is an inherited blood disorder caused by a point
mutation in hemoglobin (Hb), the protein in the red blood cell (RBC) responsible for the …

Background Sickle cell disease is a fatal systemic condition characterized by acute painful
episodes, persistent anemia, ongoing organ damage, organ infarction, and a markedly …

Patients with sickle cell disease (SCD) often experience painful vaso‐occlusive crises and
chronic haemolytic anaemia, as well as various acute and chronic complications, such as …

A novel approach has been developed for the synthesis of Voxelotor, which is used for the
treatment of Sickle Cell Disease (SCD). The key steps involved in this approach are the ring …

Two generations ago, SCA was recognized as the first “molecular disease.” 2 This launched
decades of research into normal and sickle hemoglobin (HbA and HbS, respectively). These …

Introduction The substitution of glutamic acid by valine on the ß-globin chain produces the
hemoglobin S variant responsible for sickle cell disease (SCD), a disorder that affects …

Rationale Sickle cell disease, a debilitating genetic disorder affecting numerous newborns
globally, has historically received limited attention in pharmaceutical research. However …